Washington, D.C. 20549



Form 8-K



Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2014




(Exact name of registrant as specified in its charter)




Delaware   001-35006   93-0979187

(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. Employer

Identification No.)

11500 S. Eastern Ave., Ste. 240

Henderson, NV 89052

(Address of principal executive offices, zip code)

Registrant’s telephone number, including area code: (702) 835-6300

Former name or former address, if changed since last report: N/A



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 7, 2014, the Board of Directors (the “Board”) of Spectrum Pharmaceuticals, Inc. (the “Company”) in consultation with the Compensation Committee of the Board, awarded its Chief Executive Officer, Rajesh C. Shrotriya, M.D., a performance-based cash bonus of $900,000 for fiscal 2013. In determining the award for Dr. Shrotriya, the Board evaluated his performance based primarily on his individual contributions toward the advancement of the Company’s business objectives. In addition, the Board used broad-based third party surveys to obtain a general understanding of current compensation practices.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2014



/s/ Kurt A. Gustafson

  Kurt A. Gustafson
  Executive Vice President and Chief Financial Officer